Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Here's What to Expect From Agilent Technologies’ Next Earnings Report

- 🧬 Agilent Technologies is a $34 billion market cap global leader providing analytical and clinical laboratory technologies, diagnostics, and applied chemical solutions.

- 📅 The company is expected to announce its fiscal second-quarter earnings for 2026 in the near future ahead of analyst reports.

- 💰 Analysts project Agilent will report a diluted profit of $1.41 per share for the upcoming quarter, representing a 7.6% increase from the previous year's $1.31 per share.

- 📊 For fiscal full-year expectations, analysts anticipate an EPS of $5.95, which would be a 6.4% rise compared to $5.59 in fiscal 2025.

- 🚀 Long-term growth is projected with expected EPS reaching $6.55 by fiscal 2027, indicating a 10.1% year-over-year increase from current estimates.

- 📉 Despite recent gains, Agilent stock has underperformed the S&P 500's 32.2% gains over the past 52 weeks but still outperformed the Health Care Select Sector ETF.

- 📉 Following its Q1 report on Feb. 25 where adjusted EPS of $1.36 missed expectations, the stock closed down more than 3% in the subsequent trading session.

- 💵 In Q1, Agilent revenue stood at $1.8 billion, meeting Wall Street forecasts while management expects full-year revenue between $7.3 billion and $7.5 billion.

- 🎯 Analysts maintain a bullish consensus with an overall "Strong Buy" rating across 16 covering analysts.

- 💡 Out of the analyst coverage group, 11 advise "Strong Buy," one suggests "Moderate Buy," and four offer a "Hold" rating.

- 🏆 The average analyst price target for Agilent stock is set at $162.64, suggesting a potential upside of approximately 42.1% from current levels.

- ⚠️ Historical performance shows the company beat or matched consensus estimates in three of the last four quarters while missing the forecast on another occasion.

Bullish Signals
  • Analysts project Agilent Technologies' fiscal second-quarter earnings per share (EPS) will reach $1.41, representing a 7.6% increase from the year-ago quarter's $1.31.
  • The company demonstrated strong consistency in recent performance, beating or matching consensus estimates in three of its last four quarters.
  • Full-year analysts expect Agilent to report an EPS of $5.95, which is a 6.4% increase from fiscal 2025's $5.59.
  • Long-term growth is highlighted with expected fiscal 2027 EPS rising 10.1% year over year to $6.55.
  • Despite underperforming the broader S&P 500, Agilent outperformed the State Street Health Care Select Sector SPDR ETF (XLV) with a 9% gain compared to 7.7% for the sector ETF.
  • The stock carries a 'Strong Buy' rating from 16 analysts, with 11 explicitly advising this rating and an average price target suggesting 42.1% upside potential.
  • Following Q1, revenue of $1.8 billion met Wall Street forecasts exactly, indicating operational resilience even after a slight miss in EPS.
Risk Factors
  • The stock has underperformed the S&P 500 Index's 32.2% gains over the past 52 weeks, with shares rising only 9% during this period.
  • Agilent's Q1 adjusted EPS of $1.36 fell short of Wall Street expectations of $1.37, causing shares to close down more than 3% in the following trading session.
  • Only four out of 16 analysts covering the stock rate it as 'Hold', suggesting a lack of universal confidence compared to the dominant bullish sentiment.
Full Analysis
Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, is a global leader valued at $34 billion that provides application-focused solutions for life sciences, diagnostics, and applied chemical markets. The company specializes in electronic and bio-analytical measurement, semiconductor, and board testing. Investors are anticipating the announcement of its fiscal second-quarter earnings for 2026, with analysts expecting a diluted profit of $1.41 per share, representing a 7.6% increase from the $1.31 per share reported in the year-ago quarter. Historically, the company has beat or matched consensus estimates in three of its last four quarters, though it missed forecasts on one occasion. Looking at broader projections, analysts forecast full-year earnings per share (EPS) of $5.95, a 6.4% rise from fiscal 2025's $5.59. Growth is expected to accelerate in fiscal 2027, with an anticipated 10.1% year-over-year increase to reach $6.55 per share. Despite these growth projections, the stock has underperformed the S&P 500 Index’s 32.2% gains over the past 52 weeks, though it managed a 9% gain during that same period. Conversely, Agilent outperformed the State Street Health Care Select Sector SPDR ETF (XLV), which saw 7.7% gains in the same timeframe. Recent performance highlights include the company's Q1 report on February 25, where shares closed down more than 3% following the results. During that quarter, adjusted EPS of $1.36 fell slightly below Wall Street expectations of $1.37, while revenue of $1.8 billion met forecasts. For the full year, management expects adjusted EPS between $5.90 and $6.04, with revenue anticipated to fall between $7.3 billion and $7.5 billion. The overall analyst consensus for Agilent stock remains bullish, supported by a "Strong Buy" rating from 11 out of 16 covering analysts, compared to one "Moderate Buy" and four "Hold" ratings. The average analyst price target is set at $162.64, suggesting potential upside of approximately 42.1% from current levels.